Safety and Occupational Health Study Section; Notice of Charter Renewal, 58376-58377 [2024-15796]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
58376
Federal Register / Vol. 89, No. 138 / Thursday, July 18, 2024 / Notices
8. Administration of tarlatamab-dlle **
9. Intraoperative Donor Organ
Protection in Renal Transplantation
10. Section X Updates
11. Addenda and Key Updates *
* Request is for an April 1, 2025,
implementation date.
** Request is for an April 1, 2025,
implementation date, and the requestor
intends to submit a new technology
add-on payment (NTAP) application for
FY 2026 consideration.
*** Requestor intends to submit an
NTAP application for FY 2026
consideration.
Presentations for procedure code
requests are conducted by both the
requestor and the Centers for Medicare
& Medicaid Services (CMS) during the
C&M Committee meeting. Discussion
from the requestor generally focuses on
the clinical issues for the procedure or
technology, followed by the proposed
coding options from a CMS analyst.
Topics presented may also include
requests for new procedure codes that
relate to a new technology add-on
payment (NTAP) policy request.
CMS has modified the approach for
presenting the NTAP-related ICD–10–
PCS procedure code requests that
involve the administration of a
therapeutic agent. For the September
10–11, 2024, ICD–10 C&M Committee
meeting, consistent with the
requirements of section
1886(d)(5)(K)(iii) of the Social Security
Act, applicants submitted requests to
create a unique procedure code to
describe the administration of a
therapeutic agent, such as the option to
create a new code in Section X within
the ICD–10–PCS procedure code
classification. CMS will initially display
only those meeting materials associated
with the NTAP-related ICD–10–PCS
procedure code requests that involve the
administration of a therapeutic agent on
the CMS website in August 2024 at:
https://www.cms.gov/medicare/codingbilling/icd-10-codes/icd-10coordination-maintenance-committeematerials.
The NTAP-related ICD–10–PCS
procedure code requests that involve the
administration of a therapeutic agent
are:
1. Administration of emapalumablzsg **
2. Administration of tarlatamab-dlle **
** Request is for an April 1, 2025,
implementation date, and the requestor
intends to submit an NTAP application
for FY 2026 consideration..
These topics will not be presented
during the September 10–11, 2024,
meeting. CMS will solicit public
VerDate Sep<11>2014
16:47 Jul 17, 2024
Jkt 262001
comments regarding any clinical
questions or coding options included for
these procedure code topics in advance
of the meeting continuing through the
end of the respective public comment
periods. Members of the public should
send any questions or comments to the
CMS mailbox at:
ICDProcedureCodeRequest@
cms.hhs.gov.
CMS intends to post a question-andanswer document in advance of the
meeting to address any clinical or
coding questions that members of the
public may have submitted. Following
the conclusion of the meeting, CMS will
post an updated question-and-answer
document to address any additional
clinical or coding questions that
members of the public may have
submitted during the meeting that CMS
was not able to address or that were
submitted after the meeting.
The NTAP-related ICD–10–PCS
procedure code requests that do not
involve the administration of a
therapeutic agent and all non-NTAPrelated procedure code requests will
continue to be presented during the
virtual meeting on September 10, 2024,
consistent with the standard meeting
process.
CMS will make all meeting materials
and related documents available at:
https://www.cms.gov/medicare/codingbilling/icd-10-codes/icd-10coordination-maintenance-committeematerials. Any inquiries related to the
procedure code topics scheduled for the
September 10–11, 2024, ICD–10 C&M
Committee meeting that are under
consideration for April 1, 2025, or
October 1, 2025, implementation should
be sent to the CMS mailbox at:
ICDProcedureCodeRequest@
cms.hhs.gov.
ICD–10–CM Topics:
1. Abnormal Rheumatoid Factor and
Anti-citrullinated Protein Antibody
Without a Diagnosis of Rheumatoid
Arthritis
2. Demodex Blepharitis
3. Encounter for Prophylactic Removal
of Fallopian Tube(s) for Persons
Without Known Genetic/Familial Risk
Factors
4. Genetic Neurodevelopmental
Disorders
5. Hypothalamic Obesity
6. Kabuki Syndrome
7. Topical Steroid Withdrawal
8. Usher Syndrome
9. Addenda
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–15795 Filed 7–17–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Safety and Occupational Health Study
Section; Notice of Charter Renewal
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice of charter renewal.
The Centers for Disease
Control and Prevention (CDC), within
the Department of Health and Human
Services (HHS), announces the renewal
of the charter of the Safety and
Occupational Health Study Section
(SOHSS).
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Joanne Fairbanks, Designated Federal
Officer, Safety and Occupational Health
Study Section, Centers for Disease
Control and Prevention, Department of
Health and Human Services, 1095
Willowdale Road, Morgantown, West
Virginia 26505. Telephone: (304) 285–
6143; Email: JFairbanks@cdc.gov.
CDC is
providing notice under 5 U.S.C. 1001
through 1014 of the renewal of the
charter of the Safety and Occupational
Health Study Section, Centers for
Disease Control and Prevention,
Department of Health and Human
Services. This charter has been renewed
for a two-year period through June 30,
2026.
SUPPLEMENTARY INFORMATION:
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
E:\FR\FM\18JYN1.SGM
18JYN1
Federal Register / Vol. 89, No. 138 / Thursday, July 18, 2024 / Notices
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–15796 Filed 7–17–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting of the Board of Scientific
Counselors, National Center for Injury
Prevention and Control
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting for the Board of
Scientific Counselors, National Center
for Injury Prevention and Control (BSC,
NCIPC). This meeting is open to the
public. Time will be available for public
comment.
DATES: The meeting will be held on
September 24, 2024, from 10 a.m. to
12:30 p.m., EDT. The public comment
period will be from 12:10 p.m. to 12:25
p.m., EDT.
ADDRESSES: Webinar, Atlanta, Georgia.
All participants must register by using
the following link to attend the meeting:
https://cdc.zoomgov.com/webinar/
register/WN_cnG74hSRR8C_
2DCCRmW5Hg.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Christopher R. Harper, Ph.D.,
Designated Federal Officer, Board of
Scientific Counselors, National Center
for Injury Prevention and Control,
Centers for Disease Control and
Prevention, 4770 Buford Highway NE,
Mailstop S–1069, Atlanta, Georgia
30341. Telephone: (404) 718–8330;
Email: ncipcbsc@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Board of Scientific
Counselors, National Center for Injury
Prevention and Control (BSC, NCIPC)
will: (1) conduct, encourage, cooperate
with, and assist other appropriate public
health authorities, scientific
institutions, and scientists in the
conduct of research, investigations,
experiments, demonstrations, and
studies relating to the causes and
VerDate Sep<11>2014
16:47 Jul 17, 2024
Jkt 262001
strategies related to the prevention of
injury, overdose, and violence; (2) assist
States and other entities in preventing
intentional and unintentional injuries,
and to promote health and well-being;
and (3) make recommendations of grants
and cooperative agreements for research
and prevention activities related to
injury, overdose, and violence. The
BSC, NCIPC makes recommendations
regarding policies, strategies, objectives,
and priorities and reviews progress
toward injury, overdose, and violence
prevention. The Board also provides
advice on the appropriate balance of
intramural and extramural research and
provides guidance on the needs,
structure, progress, and performance of
intramural programs. Further, the Board
provides guidance on extramural
scientific program matters.
Additionally, the Board provides
second-level scientific and
programmatic review of applications for
research grants, cooperative agreements,
and training grants related to injury,
overdose, and violence prevention, and
recommends approval of projects that
merit further consideration for funding
support. The Board also provides
feedback and input on strategic plans,
resources, and priority publications
related to injury, overdose, and violence
prevention.
Matters to be Considered: The agenda
will include discussions on the Updated
Child Abuse and Neglect Research
Priorities and the Updated Youth and
Community Violence Research
Priorities. Agenda items are subject to
change as priorities dictate.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–15793 Filed 7–17–24; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
58377
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2024–0055; NIOSH 232]
Meeting of the Board of Scientific
Counselors, National Institute for
Occupational Safety and Health,
National Firefighter Registry
Subcommittee
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting of the Board of
Scientific Counselors, National Institute
for Occupational Safety and Health
(BSC, NIOSH), National Firefighter
Registry Subcommittee. This meeting
will take place in person and virtually.
It is open to the public, limited only by
the space available (approximately 80
seats) and the number of web
conference lines available (500 lines).
Time will be available for public
comment.
SUMMARY:
The meeting will be held on
August 22, 2024, from 9 a.m. to 3:30
p.m., EDT.
Written comments must be received
on or before August 15, 2024.
ADDRESSES: Centers for Disease Control
and Prevention, Alice Hamilton
Laboratory Building, 5555 Ridge
Avenue, Cincinnati, Ohio 45213. The
conference room will have seating for
approximately 80 people.
Please note that the meeting location
is a Federal facility and in-person access
is limited to United States citizens
unless prior authorizations, taking up to
30 to 60 days, have been made. Visitors
must follow all directions for access to
CDC facilities. Instructions for visitors
to CDC, including safety requirements
related to COVID–19, are available at
https://www.cdc.gov/screening/
visitors.html.
If you wish to attend the meeting
either in person or virtually, please
register at the NIOSH website at https://
www.cdc.gov/niosh/scientificcounselors/nfrs.html or by telephone at
(404) 498–1650 no later than August 15,
2024. If you are attending virtually, you
will receive the Zoom web conference
access information after registering.
You may submit comments, identified
by Docket No. CDC–2024–0055;
DATES:
E:\FR\FM\18JYN1.SGM
18JYN1
]]>Agencies
[Federal Register Volume 89, Number 138 (Thursday, July 18, 2024)]
[Notices]
[Pages 58376-58377]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-15796]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Safety and Occupational Health Study Section; Notice of Charter
Renewal
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of charter renewal.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), within
the Department of Health and Human Services (HHS), announces the
renewal of the charter of the Safety and Occupational Health Study
Section (SOHSS).
FOR FURTHER INFORMATION CONTACT: Joanne Fairbanks, Designated Federal
Officer, Safety and Occupational Health Study Section, Centers for
Disease Control and Prevention, Department of Health and Human
Services, 1095 Willowdale Road, Morgantown, West Virginia 26505.
Telephone: (304) 285-6143; Email: [email protected].
SUPPLEMENTARY INFORMATION: CDC is providing notice under 5 U.S.C. 1001
through 1014 of the renewal of the charter of the Safety and
Occupational Health Study Section, Centers for Disease Control and
Prevention, Department of Health and Human Services. This charter has
been renewed for a two-year period through June 30, 2026.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
[[Page 58377]]
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-15796 Filed 7-17-24; 8:45 am]
BILLING CODE 4163-18-P
